Question to the Department of Health and Social Care:

To ask His Majesty's Government what estimate have they made of the effect of the agreement recently concluded between the UK and USA as part of the Economic Prosperity Deal on the cost of purchasing drugs for the NHS for each of the financial years 2025/26, 2026/27, 2027/28, and 2028/29; and whether any such costs were included in planning for the recent Budget 2025.

Every patient deserves access to the best possible treatment. This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences sector.

Costs will start smaller but will increase over time as the National Institute for Health and Care Excellence (NICE) approves more life improving and lifesaving medicines. Total costs over the Spending Review period are expected to be approximately £1 billion. But the final costs will clearly depend on which medicines NICE decides to approve and the actual uptake of these. This is not something that we can pre-empt at this time as it depends on which drugs come to market, and which are assessed as approved for use on the NHS accordingly.

At the Spending Review we delivered a record real terms increase for day-to-day spending for the NHS in England up to April 2029. This deal will be funded by allocations made at the Spending Review, where front line services will remain protected through the record funding secured. Future year funding will be settled at the next Spending Review.